Table 1.
Clinical and biochemical characteristics of the whole prevalent population, othe the 20 patients enrolled in the intensive phase and, by comparison, of the 10 patients excluded from this phase. Data are M ± SE.
| Patients | (n = 30) | (n = 20) | (n = 10) | 20 vs 10 p< |
|---|---|---|---|---|
| Men/Females; n (%) | 13 (43)/17 (57) | 8 (40)/12 (60) | 5 (50)/5(50) | n.s |
| Age, yr | 77 ± 2.3 | 75 ± 2.9 | 76 ± 2.9 | n.s |
| Vintage HD, yr | 3.0 ± 0.7 | 3.7 ± 0.7 | 2,4 ± 0.6 | 0.02 |
| BMI, Kg/m2 | 24.1 ± 1.3 | 25.1 ± 1.2 | 22.1 ± 0,7 | 0.03 |
| ABI | 0.6 ± 0.06 | 0.7 ± 0.06 | 0.6 ± 0.05 | n.s |
| Comorbidities; n (%) | 15 (50) | 12 (60) | 3 (30) | n.s (#) |
| Obesity (BMI > 30) | 3 (10) | 2 (10) | 1 (3) | |
| Diabetes, n (%) | 11 (36) | 7 (35) | 4 (13) | |
| Vascular co-morbidities* | 8 (25) | 5 (25) | 3 (30) | |
| Hb, g/dl | 10.0 ± 0.4 | 10.3 ± 0.3 | 9.4 ± 0.4 | n.s |
| Calcium, mg/dl | 8.4 ± 0.3 | 8.5 ± 0.1 | 8.3 ± 0.22 | n.s |
| Phosphate, mg/dl | 5.0 ± 0.5 | 5.2 ± 0.3 | 4.6 ± 0.6 | n.s |
| PTH, pg/ml | 286 ± 30 | 338 ± 35 | 272 ± 26 | n.s |
| ALP, UI/L | 79 ± 5,1 | 84 ± 5,9 | 81 ± 10 | n.s |
| CRP, mg/dl | 2.2 ± 0.5 | 2.1 ± 0.6 | 1.5 ± 0.6 | n.s |
| ESR, mm | 36 ± 4.7 | 36 ± 4.7 | 24 ± 14 | n.s |
| Ferritin, mcg/l | 345 ± 43 | 321 ± 46 | 337 ± 84 | n.s |
| Transferrin, mg/dl | 174 ± 12 | 179 ± 13 | 148 ± 16 | n.s |
| Albumin, g/dl | 3.1 ± 0.1 | 3.3 ± 0.06 | 2.9 ± 0.20 | n.s |
| KT/V | 1.40 ± 0.06 | 1.48 ± 0.04 | 1.37 ± 0.05 | n.s |
| nPCR, g/Kg/day | 1.00 ± 0.07 | 1.03 ± 0.04 | 0.95 ± 0.03 | n.s |
*Vascular co-morbidities = Peripheral ischemia and acute Coronary Syndrome.
BMI: Body Mass Index; ABI: Ankle Brachial Index; Hb: Haemoglobin; PTH: intact Parathyroid hormone; ALP: Alkaline Phosphate; CRP: C-reactive protein; ESR: Erythrocyte Sedimentation Rate; nPCR: normalized Protein Catabolic Rate. All comparisons are t-test, except for X2 test (#) applied for comorbidities.